ClinicalTrials.gg
CompletedNCT00171314Updated Apr 11, 2012Results posted

The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer

A Phase 3 interventional study of Zoledronic acid and Letrozole in Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 49 sites in 9 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
527
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing Zoledronic Acid in Breast Neoplasms — none open to participants now, 2 under way, 1 of them phase 3. Zoledronic Acid · Breast Neoplasms.

Enrollment
11th of 56
527 · median 98
Started
2004
with 4 others
Phase 3
24 of 59
none open now
Registered
11th of 59
by date
Lead sponsor
11 of 59
Novartis Pharmaceuticals

Among the 59 studies testing Zoledronic Acid in Breast Neoplasms, this one is the 11th largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2004, is one of 24 in phase 3, and was the 11th registered.

Breast Neoplasms

14,832 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 59 studies testing Zoledronic Acid in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About Zoledronic Acid

Zoledronic Acid: first FDA approval 2001 (ZOMETA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 59 studies testing Zoledronic Acid in Breast Neoplasms as a file.
02

Study summary

Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every 6 months or delayed start zoledronic acid 4 mg IV 15-minute infusion every 6 months. Delayed start zoledronic acid will be initiated when either the Bone Mineral Density T-score is below -2 Standard Deviations at either the lumbar spine or hip or any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the month 36 scheduled visit. Letrozole 2.5 mg will be given daily for 5 years.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • breast cancer
  • letrozole
  • zoledronic acid
  • adjuvant
  • postmenopausal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stage I-IIIa breast cancer
  • Recent surgery for breast cancer

Exclusion criteria

Exclusion Criteria:

  • disease
  • Invasive bilateral disease
  • Clinical or radiological evidence of existing fracture in spine or hip

Other protocol-defined inclusion / exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
527 participants (actual)

Study arms

  • Experimental
    Upfront Zoledronic Acid

    Zoledronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1

    Drug: Zoledronic acid · Drug: Letrozole

  • Experimental
    Delayed Zoledronic Acid

    Zoledronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score \<= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1

    Drug: Zoledronic acid · Drug: Letrozole

Interventions

  • Zoledronic acid 4 mg Intravenous (IV)15 minute infusion every 6 months.

    Also known as: ZOL446, Zometa®

  • Letrozole tablets 2.5 mg/day/taken orally for 5 years.

    Also known as: Femara®

06

What researchers measure

Primary outcomes

  1. Percent Change in Lumbar Spine (L2-L4) BMD After 12 Months of Letrozole Therapy

    Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(BMD at Visit - BMD at Baseline) / BMD at Baseline\] \* 100.

    Time frame: From Baseline - 12 months

Secondary outcomes

  1. Percent Change in Lumbar Spine (L2-L4) BMD at 2 Years, 3 Years, 4 Years and 5 Years

    Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(BMD at Visit - BMD at Baseline) / BMD at Baseline\] \* 100.

    Time frame: From Baseline to Year 2, Year 3, Year 4, Year 5

  2. Percent Change in Lumbar Spine (L1-L4) BMD at Year 1, Year 2, Year 3, Year 4 and Year 5

    Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(BMD at Visit - BMD at Baseline) / BMD at Baseline\] \* 100.

    Time frame: From Baseline to Year 1, Year 2, Year 3, Year 4, Year 5

  3. Percent Change in Total Hip BMD at Year 1, Year 2, Year 3, Year 4 and Year 5

    Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(BMD at Visit - BMD at Baseline) / BMD at Baseline\] \* 100.

    Time frame: From baseline to Year 1, Year 2, Year 3, Year 4, Year 5

  4. Percentage of Participants With Radiological (Vertebra) Fractures Which Were Not Present at Baseline But Were Present at Year 3

    Radiological Fracture at 36 months which was not present at baseline = (new fracture/number participant analyzed)\*100. Evaluation of radiological fractures were based on central lab X-ray data. A subject with multiple fractures at the same time or multiple fractures with the same grade is counted only once for that treatment.

    Time frame: Year 3

07

Results

Posted Apr 11, 2012

Participant flow

Participant flow — Overall Study
MilestoneUpfront Zoledronic AcidDelayed Zoledronic Acid
Started263264
Safety population254269
Completed172186
Not completed9178
Withdrew: Adverse event4441
Withdrew: Lack of efficacy1914
Withdrew: Withdrawal by subject96
Withdrew: Abnormal test procedure results93
Withdrew: Protocol violation37
Withdrew: Administrative problems43
Withdrew: Lost to follow-up13
Withdrew: Death21

Outcome measures

PrimaryPercent Change in Lumbar Spine (L2-L4) BMD After 12 Months of Letrozole Therapy

Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(BMD at Visit - BMD at Baseline) / BMD at Baseline\] \* 100.

Time frame:
From Baseline - 12 months
Reported as:
Mean · Percent Change
Percent Change in Lumbar Spine (L2-L4) BMD After 12 Months of Letrozole Therapy
Percent ChangeUpfront Zoledronic AcidDelayed Zoledronic Acid
Percent Change in Lumbar Spine (L2-L4) BMD After 12 Months of Letrozole Therapy2.680 ± 2.8451-3.314 ± 3.9632
SecondaryPercent Change in Lumbar Spine (L2-L4) BMD at 2 Years, 3 Years, 4 Years and 5 Years

Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(BMD at Visit - BMD at Baseline) / BMD at Baseline\] \* 100.

Time frame:
From Baseline to Year 2, Year 3, Year 4, Year 5
Reported as:
Mean · Percent Change
Percent Change in Lumbar Spine (L2-L4) BMD at 2 Years, 3 Years, 4 Years and 5 Years
Percent ChangeUpfront Zoledronic AcidDelayed Zoledronic Acid
Year 2 (n=122,142)4.136 ± 3.8182-3.924 ± 4.7442
Year 3 (n=119,133)4.777 ± 4.8959-4.297 ± 5.3583
Year 4 (n=104, 122)5.462 ± 5.2922-4.746 ± 5.6588
Year 5 (n=86, 102)6.013 ± 5.4366-4.572 ± 6.1617
SecondaryPercent Change in Lumbar Spine (L1-L4) BMD at Year 1, Year 2, Year 3, Year 4 and Year 5

Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(BMD at Visit - BMD at Baseline) / BMD at Baseline\] \* 100.

Time frame:
From Baseline to Year 1, Year 2, Year 3, Year 4, Year 5
Reported as:
Mean · Percent Change
Percent Change in Lumbar Spine (L1-L4) BMD at Year 1, Year 2, Year 3, Year 4 and Year 5
Percent ChangeUpfront Zoledronic AcidDelayed Zoledronic Acid
Year 1 (n=123, 156)2.330 ± 2.7465-3.532 ± 3.7830
Year 2 (n=122, 142)3.994 ± 3.6344-3.934 ± 4.7162
Year 3 (n=199, 133)4.523 ± 4.5197-4.292 ± 5.2317
Year 4 (n=104, 122)5.051 ± 4.9739-4.713 ± 5.4101
Year 5 (n=86, 102)5.476 ± 5.0395-4.692 ± 6.0242
SecondaryPercent Change in Total Hip BMD at Year 1, Year 2, Year 3, Year 4 and Year 5

Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(BMD at Visit - BMD at Baseline) / BMD at Baseline\] \* 100.

Time frame:
From baseline to Year 1, Year 2, Year 3, Year 4, Year 5
Reported as:
Mean · Percent Change
Percent Change in Total Hip BMD at Year 1, Year 2, Year 3, Year 4 and Year 5
Percent ChangeUpfront Zoledronic AcidDelayed Zoledronic Acid
Year 1 (n=173, 187)1.637 ± 2.4371-1.644 ± 2.9994
Year 2 (n=169, 168)2.119 ± 2.9435-2.628 ± 3.5659
Year 3 (n=163, 162)1.991 ± 3.4207-3.011 ± 4.7684
Year 4 (n=145, 152)2.439 ± 3.5236-3.074 ± 5.4515
Year 5 (n=119, 121)2.788 ± 3.8386-4.012 ± 5.1321
SecondaryPercentage of Participants With Radiological (Vertebra) Fractures Which Were Not Present at Baseline But Were Present at Year 3

Radiological Fracture at 36 months which was not present at baseline = (new fracture/number participant analyzed)\*100. Evaluation of radiological fractures were based on central lab X-ray data. A subject with multiple fractures at the same time or multiple fractures with the same grade is counted only once for that treatment.

Time frame:
Year 3
Reported as:
Number · Percentage of Participants
Percentage of Participants With Radiological (Vertebra) Fractures Which Were Not Present at Baseline But Were Present at Year 3
Percentage of ParticipantsUpfront Zoledronic AcidDelayed Zoledronic Acid
Percentage of Participants With Radiological (Vertebra) Fractures Which Were Not Present at Baseline But Were Present at Year 32.83.3

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Upfront Zoledronic Acid—47/254 (18.5%)225/254 (88.6%)
Delayed Zoledronic Acid—56/269 (20.8%)240/269 (89.2%)
Most frequent serious events
Showing 10 of 148
Most frequent serious events
EventUpfront Zoledronic AcidDelayed Zoledronic Acid
OsteoarthritisMusculoskeletal and connective tissue disorders2/2545/269
Cardiac failureCardiac disorders4/2541/269
Osteonecrosis of jawMusculoskeletal and connective tissue disorders3/2541/269
Ovarian cystReproductive system and breast disorders3/2541/269
Angina pectorisCardiac disorders0/2543/269
FallInjury, poisoning and procedural complications2/2543/269
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/2543/269
DepressionPsychiatric disorders0/2543/269
Myocardial infarctionCardiac disorders2/2540/269
Ankle fractureInjury, poisoning and procedural complications2/2540/269
Most frequent other events
Showing 10 of 32
Most frequent other events
EventUpfront Zoledronic AcidDelayed Zoledronic Acid
ArthralgiaMusculoskeletal and connective tissue disorders123/254136/269
Hot flushVascular disorders66/254101/269
FatigueGeneral disorders46/25457/269
Pain in extremityMusculoskeletal and connective tissue disorders26/25446/269
Back painMusculoskeletal and connective tissue disorders41/25436/269
AstheniaGeneral disorders26/25436/269
MyalgiaMusculoskeletal and connective tissue disorders33/25435/269
Weight increasedInvestigations33/25423/269
Musculoskeletal painMusculoskeletal and connective tissue disorders26/25434/269
HypertensionVascular disorders32/25425/269

Baseline characteristics

Age Continuous
Age Continuous(years)Upfront Zoledronic AcidDelayed Zoledronic AcidTotal
Mean58.2 ± 8.1958.4 ± 7.7358.29 ± 7.96
Sex: Female, Male
Sex: Female, Male(Participants)Upfront Zoledronic AcidDelayed Zoledronic AcidTotal
Female263264527
Male000
08

Study locations

49 sites
  • Novartis Investigative Site
    Buenos Aires, Argentina
  • Novartis Investigative Site
    Rosario - Santa Fe, Argentina
  • Novartis Investigative Site
    Aalst, Belgium
  • Novartis Investigative Site
    Anderlecht, Belgium
  • Novartis Investigative Site
    Bonheiden, Belgium
  • Novartis Investigative Site
    Brasschaat, Belgium
  • Novartis Investigative Site
    Bruxelles, Belgium
  • Novartis Investigative Site
    Edegem, Belgium
  • Novartis Investigative Site
    Hasselt, Belgium
  • Novartis Investigative Site
    Leuven, Belgium
  • Novartis Investigative Site
    Libramont-Chevigny, Belgium
  • Novartis Investigative Site
    Liège, Belgium
  • Novartis Investigative Site
    Mons, Belgium
  • Novartis Investigative Site
    Ottignies, Belgium
  • Novartis Investigative Site
    St. Niklaas, Belgium
  • Novartis Investigative Site
    Wilrijk, Belgium
  • Novartis Investigative Site
    Yvoir, Belgium
  • Novartis Investigative Site
    Limoges, France
  • Novartis Investigative Site
    Mougins, France
  • Novartis Investigative Site
    Perigueux Cedex, France
  • Novartis Investigative Site
    Rennes, France
  • Novartis Investigative Site
    Saint Brieuc Cedex, France
  • Novartis Investigative Site
    Saint-Herblain Cedex, France
  • Novartis Investigative Site
    Toulon Cedex, France
  • Novartis Investigative Site
    Vandoeuvre Les Nancy Cedex, France
  • Novartis Investigative Site
    Genova, Italy
  • Novartis Investigative Site
    Ivrea, Italy
  • Novartis Investigative Site
    Lecco, Italy
  • Novartis Investigative Site
    Monteforte Irpino (Av), Italy
  • Novartis Investigative Site
    Pietra Ligure, Italy
  • Novartis Investigative Site
    Roma, Italy
  • Novartis Investigative Site
    Sassari, Italy
  • Novartis Investigative Site
    Torino, Italy
  • Novartis Investigative Site
    Vicenza, Italy
  • Novartis Investigative Site
    Daegu, Korea, Republic of
  • Novartis Investigative Site
    Jeollanam-do, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea, Republic of
  • Novartis Investigative Site
    Den Haag, Netherlands
  • Novartis Investigative Site
    Eindhoven, Netherlands
  • Novartis Investigative Site
    Hoogeveen, Netherlands
  • Novartis Investigative Site
    Nijmegen, Netherlands
  • Novartis Investigative Site
    Riyadh, Saudi Arabia
  • Novartis Investigative Site
    Cape Town, South Africa
  • Novartis Investigative Site
    Durban, South Africa
  • Novartis Investigative Site
    Johannesburg, South Africa
  • Novartis Investigative Site
    Barcelona, Spain
  • Novartis Investigative Site
    Cordoba, Spain
  • Novartis Investigative Site
    Madrid, Spain
  • Novartis Investigative Site
    Valencia, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004 and a primary completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 15, 2005
Start
Mar 2004
Primary completionActual
Nov 2010
Results first posted
Apr 11, 2012
Last update
Apr 11, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00171314
Responsible party
Sponsor
First posted
Sep 15, 2005
Start date
Mar 2004
Primary completion
Nov 2010
Results posted
Apr 11, 2012
Last update
Apr 11, 2012

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zoledronic Acid · Letrozole

Start the discussion